An observational study in Ischaemic Stroke, sponsored by Li Haiyan. Status unknown at 1 site in China. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2012-08-15.
Sponsored by Li Haiyan · Observational
Negligence or contempt of the etiology and pathogenesis of minor ischaemic stroke in the early diagnosis and effective treatment leads to more than 40-50% of patient with recurrent episodes, and 10% patient died. Therefore, diagnosis and treatment of minor ischaemic stroke according to the etiology and pathogenesis is important.
The 2007 Korean modified TOAST type got some progress, but there exists two major disadvantages: imperfect diagnosis and pathogenesis of perforator artery infarction etiology; lack of typing according to the pathogenesis of large atherosclerotic infarction and taking measures of treatment according to the new types. Recently, domestic professor Gaoshan proposes new approach to diagnose and treat minor ischaemic stroke according to the etiology and pathogenesis of CISS typing, but the pathogenesis of hypoperfusion infarction with severe stenosis of large artery is unclear. Is it low perfusion? Or artery-artery embolization? Or both? How to distinguish the pathogenesis of branch artery disease: by atherosclerosis? Or hyalinosis? Or both? How to check the validity of clinical types? This study take different interventions according to different types and observation of the long term clinical results of intervention( mortality, recurrence rate, disability rate and rate of cerebral hemorrhage and subarachnoid hemorrhage), in order to clarify the new types can indeed solve the current problem of minor ischaemic stroke with high mortality, recurrence rate, disability rate and rate of cerebral hemorrhage and subarachnoid hemorrhage.
7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 160 across 1,692 observational studies indexed under Stroke.
Browse Stroke studies →This is the only study on the registry with Li Haiyan as lead sponsor.
Counted across the registry records on this site, refreshed daily.
patients with new emergence of minor ischaemic stroke ( one of two conditions: (1) conscious patients with any of NIHSS score = 1,or (2) NIHSS ≤ 3 )
one of two conditions:
Exclusion Criteria:
There is no hypoperfusion ( contralateral compensatory is good )
Contralateral compensatory not sufficient
Hypoperfusion and embolus amotic
This study is status unknown, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.